Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Goserelin Acetate

The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH). Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04) [from NCI]

MedGen UID:
148598
Concept ID:
C0700476
Pharmacologic Substance
2.

Malignant tumor of prostate

The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, being African-American, and some genetic changes. Symptoms of prostate cancer may include: -Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling. -Low back pain. -Pain with ejaculation. Your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (PSA). Other tests include ultrasound, x-rays, or a biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
138169
Concept ID:
C0376358
Neoplastic Process
3.

Goserelin

A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer. [from MeSH]

MedGen UID:
47799
Concept ID:
C0120107
Pharmacologic Substance
4.

Flutamide

An antiandrogen with about the same potency as cyproterone in rodent and canine species. [from MeSH]

MedGen UID:
4748
Concept ID:
C0016384
Pharmacologic Substance
5.

Prostate cancer

A cancer of the prostate. [from HPO]

MedGen UID:
506673
Concept ID:
CN167851
Finding
6.

Acetate

salts or esters of acetic acid in which the terminal hydrogen atom is replaced by a metal, for instance copper acetate Cu(CH3COO)2, or where substitution is by a radical, for instance ethyl acetate CH3COOC2H5. [from CRISP]

MedGen UID:
452099
Concept ID:
C0000975
Pharmacologic Substance
7.

Neoplasm

A malignant tumor at the original site of growth. [from NCI]

MedGen UID:
227011
Concept ID:
C1306459
Neoplastic Process
8.

Thymus Epithelial Neoplasm

MedGen UID:
220416
Concept ID:
C1266101
Neoplastic Process
9.

PMS-Flutamide

MedGen UID:
339146
Concept ID:
C1567458
Pharmacologic Substance
10.

Apo-Flutamide

MedGen UID:
339125
Concept ID:
C1567365
Pharmacologic Substance
11.

Prostica

MedGen UID:
309160
Concept ID:
C1517263
Pharmacologic Substance
12.

Prostacur

MedGen UID:
309159
Concept ID:
C1517261
Pharmacologic Substance
13.

Apimid

MedGen UID:
309155
Concept ID:
C1517245
Pharmacologic Substance
14.

Fluta-cell

MedGen UID:
297994
Concept ID:
C1567369
Pharmacologic Substance
15.

Flutexin

MedGen UID:
292602
Concept ID:
C1567371
Pharmacologic Substance
16.

Cytamid

MedGen UID:
292601
Concept ID:
C1567366
Pharmacologic Substance
17.

Novo-Flutamide

MedGen UID:
291326
Concept ID:
C1567372
Pharmacologic Substance
18.

Flutandrona

MedGen UID:
291325
Concept ID:
C1567370
Pharmacologic Substance
19.

Flumid

MedGen UID:
291323
Concept ID:
C1567367
Pharmacologic Substance
20.

Testotard

MedGen UID:
275901
Concept ID:
C1517267
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...